Shree Ganesh Remedies Limited reported Q1FY26 financial results, showing moderated growth.

Revenue was 24.67 Cr (-0.45% YoY), while PAT stood at 3.44 Cr (-26.09% YoY), and EBITDA was 7.30 Cr (-10.19% YoY) with margins at 29.6%. The company attributed this to contract repricing in its CRAMS business, European market headwinds, and domestic competition, leading to more normalized profitability.

Despite near-term challenges, management remains confident in its CRAMS vertical, noting new projects, a pilot facility completion this quarter, and accelerated Block 7 construction to support future growth and scale-up.